SELLAS Life Sciences Group, Inc.received approval of its Investigational Medicinal Product Dossier from the French regulatory authority, Agence Nationale de Sécurité du Médicament et des Produits de Santé, to advance in France its pivotal Phase III REGAL study of galinpepimut-S in patients with Acute Myeloid Leukemia who have achieved complete remission after second-line anti-leukemic therapy.
[SELLAS Life Sciences Group, Inc]
BRD9 expression was found to be elevated in hepatocellular carcinoma (HCC) through data mining of public databases. Scientists confirmed that the expression of BRD9 was increased in HCC tissues compared with that in adjacent non-tumor tissues. The upregulated level of BRD9 was also observed in HCC cells in comparison to LO2 cells.
[Cell Death & Disease]
[zotpress userid=’6630899′ items=’CCKL8ILJ’ style=’apa’ cite=’yes’]
This authors summarize the role of all-trans retinoic acid in normal hematopoiesis and in acute myeloid leukemia (AML), focusing on its impact on AML stem cells.
[zotpress userid=’1254621′ items=’YWJUZZHZ’ style=’apa’ cite=’yes’]
The authors investigated the anticancer effects of CC1007 in breakpoint cluster region-Abelson 1 fusion gene-negative (BCR-ABL1−) pre-B-ALL cell lines and primary patient-derived BCR-ABL1− pre-B-ALL cells.
[Cell Death & Disease]
[zotpress userid=’6445212′ items=’MHAM5JZM’ style=’apa’ cite=’yes’]
The authors evaluated the efficacy of ponatinib against chronic myeloid leukemia (CML) leukemic stem cells-containing lin −Sca-1 +c-Kit + cells using a mouse CML-like model.
[zotpress userid=’6807162′ items=’PLZHJ4R4′ style=’apa’ cite=’yes’]
Ascentage Pharma announced that the FDA has granted APG-2575, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.
[Ascentage Pharma (PRNewswire,LLC)]
The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
[The Leukemia & Lymphoma Society (PRNewswire,LLC)]
Scientists evaluated the involvement of antiapoptotic Bcl‐2 proteins in TNF‐related apoptosis‐inducing ligand (TRAIL) resistance. They were targeted by small interfering RNA‐mediated silencing in TRAIL‐sensitive and in TRAIL‐resistant melanoma cell lines.
[zotpress userid=’6807162′ items=’JMSPDZL7′ style=’apa’ cite=’yes’]
Investigators compared outcomes of such patients given either allo-hematopoietic stem cell transplantation (HCT) or autologous (auto)-HCT. Inclusion criteria consisted of adult patients with de novo AML, isolated trisomy 8, first HCT between 2000 and 2018, CR1 at transplantation, and either auto-HCT or allo-HCT with a HLA-identical sibling donor or a 10/10 HLA-matched unrelated donor.
[Bone Marrow Transplantation]
[zotpress userid=’6445212′ items=’WQC9HU7′ style=’apa’ cite=’yes’]
Authors summarize and discuss different drugs inhibiting the action of STAT3 and used in treatment of different types of cancer.
[zotpress userid=’6807162′ items=’VYAQBWQ7′ style=’apa’ cite=’yes’]
Bristol Myers Squibb announced that the FDA has approved Onureg® for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.
[Bristol Myers Squibb, Inc.]